BRIGHTON, UNITED KINGDOM--(Marketwire - Aug 15, 2011) - Destiny Pharma Limited, a clinical stage pharmaceutical company focused on combating antimicrobial drug resistance, announced today that its lead drug, XF-73, has been selected for Phase I clinical evaluation by NIAID. XF-73 is under development for the prevention of post-surgical Staphylococcal infections. The collaboration, which will be funded by NIAID, will be conducted under a Clinical Trial Agreement between Destiny Pharma and NIAID.
This award was driven by NIAID's interest in innovative approaches to address antimicrobial resistance and will utilize its clinical research infrastructure to support the clinical evaluation of drugs that have potential to address significant public health needs. The Phase I study of XF-73 will be its first clinical evaluation in the U.S. and will seek to provide safety, tolerability and preliminary anti-Staphylococcal activity of the drug.
XF-73, the lead drug candidate in Destiny's XF Drug portfolio, has demonstrated a unique ability to prevent the emergence of antibacterial resistance1 as compared to currently available antibiotics. It has also been shown to be potent against a wide range of Staphylococcal strains, including prevalent drug-resistant strains.
XF-73, a novel dicationic porphyrin, has rapid bactericidal activity against Gram-positive bacteria including Staphylococcus aureus, which is the number one global cause of hospital-acquired bacterial infections. The worldwide burden of Staphylococcus aureus infections is considerable. In the U.S. alone, the Centers for Disease Control and Prevention (CDC) estimates that the drug-resistant form of the bacteria Methicillin-Resistant Staphylococcus aureus (MRSA) is responsible for 19,000 deaths per year,2 and the annual cost of Staphylococcus aureus infection is put at $9.5 billion3.
Dr. Bill Love, CEO, Destiny Pharma, commented, "Signing this agreement with NIAID is a significant moment in the development of XF-73, our lead XF Drug. We look forward to working with this world-leading institution and the highly experienced clinical research contractors it brings to initiate XF-73's clinical evaluation in the U.S."
1. Farrell D, et al. Investigation of the Potential for Mutational Resistance to XF-73, Retapamulin, Mupirocin, Fusidic Acid, Daptomycin, and Vancomycin in Methicillin-Resistant Staphylococcus aureus Isolates during a 55-Passage Study. Antimicrobial Agents and Chemotherapy (2011); 55: 1177-1181 No. 3
3. Noskin GA, et al. The burden of Staphylococcus aureus on hospitals in the United States: an analysis of the 2000 and 2001 Nationwide inpatient sample database. Arch Intern Med (2005); 165: 1756-61
About Destiny Pharma:
Destiny Pharma, a clinical stage pharmaceutical company, was founded in 1997. The Company focuses on the R&D of new antimicrobial drugs, with an emphasis on novel mechanisms of action which seek to address a top 3 global healthcare issue, namely, microbial drug resistance. XF-73 is the Company's lead drug which has completed Phase I clinical development in the UK. Through its extensive business network and strategic partnerships, Destiny Pharma intends to globally commercialise candidates from the XF Drug platform which are differentiated by design from traditional antibiotics.
About the NIH and NIAID
The National Institutes of Health (NIH) is the U.S. National Medical Research Agency and includes 27 institutes and Centers and is a component of the U.S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research and it investigates the causes, treatments and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
The National Institute of Allergy and Infectious Diseases (NIAID) conducts and supports research -- at NIH, within the U.S. and worldwide -- to study the causes of infections and immune-mediated diseases and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website at www.niaid.nih.gov.
Forward Looking Statement:
This press release contains forward looking statements that are subject to risks and uncertainties and includes statements that are not historical facts. Actual results could differ significantly from results discussed. Destiny Pharma disclaims any intent or obligation to update forward looking statements except as required by law.
For further information about NIAID, visit www.niaid.nih.gov